| Nome |
# |
|
Is autonomic nervous system involved in restless legs syndrome during wakefulness?, file e291c0d4-a4fc-cddb-e053-3a05fe0aa144
|
554
|
|
Inverse correlation between VEGF and soluble VEGF receptor 2 in POEMS with AIDP responsive to intravenous immunoglobulin, file e291c0d3-97e4-cddb-e053-3a05fe0aa144
|
493
|
|
Signs and symptoms of COVID-19 in patients with multiple sclerosis, file 0148fc03-48d0-4bcd-8b19-97f9cf4cb38b
|
334
|
|
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression, file e291c0d6-0a50-cddb-e053-3a05fe0aa144
|
203
|
|
RANTES correlates with inflammatory activity and synaptic excitability in multiple sclerosis, file e291c0d6-0dfe-cddb-e053-3a05fe0aa144
|
197
|
|
Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial, file e291c0d4-7ddf-cddb-e053-3a05fe0aa144
|
167
|
|
Validation of the nerve axon reflex for the assessment of small nerve fibre dysfunction, file e291c0d6-2eba-cddb-e053-3a05fe0aa144
|
163
|
|
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study, file e8f1536a-f09b-40c0-9f06-8f3438846c7c
|
125
|
|
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study, file 325c961c-a955-4c70-af7c-5c5bfc9b49c6
|
96
|
|
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple Sclerosis, file e291c0d8-abed-cddb-e053-3a05fe0aa144
|
60
|
|
Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy, file 1cfbf4b1-4a1b-47a1-a881-8f666fa529d6
|
45
|
|
Association of HLA-DQB1∗05:02 and DRB1∗16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis, file 0a2bca7a-7637-43e0-ac6a-a3a9208adc98
|
23
|
|
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab, file 877238d5-e3cc-4760-95af-b33d8a358c84
|
14
|
|
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis, file cec7e781-9506-4031-90b0-1c7649948541
|
12
|
|
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab, file 00a5d1e2-061b-4754-8fc3-77984c946481
|
11
|
|
Anti-HBs titers are not decreased after treatment with oral cladribine in patients with multiple sclerosis vaccinated against hepatitis B virus, file 29747c4d-c39c-42a9-9821-f61de6c5e239
|
10
|
|
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France, file df929ecb-dc74-4c06-b8dd-4cc8a9ef55fc
|
10
|
|
Hereditary spastic paraplegia: a novel mutation and expansion of the phenotype variability in SPG10, file b24950b4-91b5-4edd-a119-6aa105efcc62
|
9
|
|
Maternal Multiple Sclerosis and Offspring's Cognitive and Behavioral Development: What Do We Know until Now?, file b6326d79-cb81-40fc-9f34-287466e86c32
|
9
|
|
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis, file f24238cc-ae23-455c-a429-9a5b332d6fad
|
9
|
|
Validity of the Italian multiple sclerosis neuropsychological screening questionnaire, file 2faa4577-69b3-4fbd-b6e8-779eb95a3da3
|
7
|
|
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications, file 4761eef2-f38e-4c2a-8b90-7b254c47a00c
|
7
|
|
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML, file e291c0d8-c49d-cddb-e053-3a05fe0aa144
|
7
|
|
Patient's point of view on the use of telemedicine in multiple sclerosis: a web-based survey, file e8be3e1d-d647-47fb-8575-0ad5791b8241
|
7
|
|
Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study, file f1422784-4368-4469-a66e-fb13d07283cc
|
7
|
|
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study, file 09cf2c56-243d-4281-9c8d-8e4aad771430
|
6
|
|
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy, file 19946c62-92d8-4fe2-aff9-355057e2242d
|
6
|
|
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment, file 5378b567-3c46-46e5-b695-66208be90f05
|
6
|
|
COVID-19 vaccine hesitancy among Italian people with multiple sclerosis, file 76e182cd-1061-472e-a25f-c36d20503583
|
6
|
|
Exposure to natalizumab during pregnancy and lactation is safe - Yes, file 7bf9763b-a1e1-41ac-996d-ae207ce8d77e
|
6
|
|
Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography, file bc404e83-59a7-4529-b9a7-ffc90fd7887d
|
6
|
|
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus, file 159328e1-fd90-43c2-a3c7-7157187bd9db
|
5
|
|
What happens after fingolimod discontinuation? A multicentre real-life experience, file 626e5b50-3c1c-4a69-90b9-74c88335409b
|
5
|
|
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection, file b6f6f2e6-5fd8-4ce4-a619-88d576ecd638
|
5
|
|
Topographical Correlation between Structural and Functional Impairment of the Macular Inner Retinal Layers in Multiple Sclerosis Eyes with a History of Optic Neuropathy, file ceb8e82e-74eb-4fd2-8492-633f1b63be5f
|
5
|
|
The Interplay Between Problematic Online Pornography Use, Psychological Stress, Emotion Dysregulation and Insomnia Symptoms During the COVID-19 Pandemic: A Mediation Analysis, file cf9ab43f-e294-4769-9f04-5897603289ec
|
5
|
|
Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis, file e291c0d8-e264-cddb-e053-3a05fe0aa144
|
5
|
|
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis, file e5435f2d-dcf3-41c0-a4a7-e056ff06d86f
|
5
|
|
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients, file f8daeeb9-e3f9-44b9-a953-7c7a27040236
|
5
|
|
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis, file 17133c49-8401-4039-825a-1d9489ffc13b
|
4
|
|
Fingolimod reduces the clinical expression of active demyelinating lesions in MS, file 2ee5f87b-61f8-49bd-8dd7-773e1ecdcb11
|
4
|
|
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment, file 328fbccc-78af-4fc2-b1fd-6b0cf2620dc4
|
4
|
|
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study, file 3600f8fb-8057-4f3e-8d6c-90c0bff03362
|
4
|
|
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis, file 3c503d4f-2d68-49b1-b905-3fc1f2417147
|
4
|
|
Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course, file 4b9bdf08-e469-41c1-9242-74fa86aabf42
|
4
|
|
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab, file 563b6ab6-7698-4287-8e85-2bc9996f26e3
|
4
|
|
Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis, file 6946e071-6e0a-4c2d-bdf0-f4a2389bbc09
|
4
|
|
Association of vitamin D serum levels and vitamin D supplementation with B cell kinetics and disease activity in Multiple Sclerosis patients treated with ocrelizumab: an Italian multi-center study, file 774808e4-9afd-411e-b7d2-52502166f74a
|
4
|
|
Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression, file 7c74cd0d-1ecb-4137-b496-1d976ab5bb4f
|
4
|
|
Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study, file 841cb4ce-b2e6-4647-8b30-32504d5417f8
|
4
|
|
Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis, file 87b4b942-f984-42db-8bba-e73fb1953899
|
4
|
|
Fingolimod reduces the clinical expression of active demyelinating lesions in MS, file 925e637c-0acb-4143-a9e9-613a5b9656d2
|
4
|
|
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis, file 9f4046c3-d54e-4882-b428-62c8f11e394a
|
4
|
|
Sars-CoV2 infection in pregnant women with multiple sclerosis, file 9f62b4c7-1de7-457a-a242-698a597c6717
|
4
|
|
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab, file aaf19c29-015e-40bc-94e1-179a2f12a624
|
4
|
|
TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis, file b3898c2a-2c8d-4e3b-8a2e-20f049b8998a
|
4
|
|
Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis, file e291c0d8-d9e7-cddb-e053-3a05fe0aa144
|
4
|
|
International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score, file ee46b151-021f-4f75-8910-804ebd08c457
|
3
|
|
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.", file f1190809-2c96-4b2c-aff2-5882cfc78884
|
3
|
|
Multifocal Electroretinogram Photopic Negative Response: A Reliable Paradigm to Detect Localized Retinal Ganglion Cells' Impairment in Retrobulbar Optic Neuritis Due to Multiple Sclerosis as a Model of Retinal Neurodegeneration, file f8fb9db5-84bd-4f8b-b540-ce485ecaa0df
|
3
|
|
Do we have enough evidence for recommending therapeutic apheresis for natalizumab-related progressive multifocal leukoencephalopathy patients? Comment on "Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for apheresis: The seventh special issue.", file 18fa3c9b-1f53-44dd-a0a2-ebfc23006c36
|
2
|
|
Correction to: Validity of the Italian multiple sclerosis neuropsychological screening questionnaire, file 1b0752af-f6be-4b5f-b28d-0775b1d551d2
|
2
|
|
Safety, tolerability and effectiveness of dimethyl fumarate in multiple sclerosis: an independent, multicenter, real-world study, file 52bb8f12-1219-4722-9717-88347fc80165
|
2
|
|
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis, file 60999056-be78-4cb3-93f9-cb341566c399
|
2
|
|
Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study, file 7725a7ea-1390-4fa1-ab8d-dea9187d5bb8
|
2
|
|
null, file 8d15f280-d692-4271-ab6d-438d37a88ef8
|
2
|
|
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study, file 9ad2d9e9-fcbf-44a9-93d1-309cb13222d0
|
2
|
|
Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod, file a1cb2146-c01d-48be-bd62-b66fbc320b17
|
2
|
|
Platelet-derived growth factor predicts prolonged relapse-free period in multiple sclerosis, file d5fe33d4-67ba-4368-930b-c2cfd05449d8
|
2
|
|
Functional assessment of outer and middle macular layers in multiple sclerosis, file e291c0d8-fd83-cddb-e053-3a05fe0aa144
|
2
|
|
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis, file e291c0d9-b7af-cddb-e053-3a05fe0aa144
|
2
|
|
Optimizing the "Time to pregnancy" in women with multiple sclerosis: the OPTIMUS Delphi survey, file 073edead-a177-433a-88a6-cc81c5297495
|
1
|
|
RELEVANCE OF DIAGNOSTIC INVESTIGATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLIRADICULONEUROPATHY: DATA FROM THE ITALIAN CIDP DATABASE, file 0d22d640-f818-47db-94f8-cc35ad1bf7f7
|
1
|
|
A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody, file 2cd087b4-4178-4b5b-bba9-d594f322a8ff
|
1
|
|
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study, file 49a02325-abf5-4a76-838b-df585b0b1d90
|
1
|
|
Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study, file 5e7501b1-b55f-446e-b42d-bdc1f162b9b3
|
1
|
|
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease, file 97baea76-c727-4397-b90c-d49fc144de45
|
1
|
|
Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab, file ab7c4b24-4d6f-41fe-b167-2bdd22e30819
|
1
|
|
Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register, file b9df67dd-c49c-4dd8-a632-d9b05096bffc
|
1
|
|
Impact of environmental factors and physical activity on disability and quality of life in CIDP, file cb483946-39f5-4f91-9d2c-34e22ce625f5
|
1
|
|
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey, file de2af2ed-fe66-4e87-843f-7ad25c4c7d2c
|
1
|
|
Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function, file e291c0d5-63b4-cddb-e053-3a05fe0aa144
|
1
|
|
Subclinical autonomic dysfunction in spinobulbar muscular atrophy (Kennedy disease), file e291c0d5-6eae-cddb-e053-3a05fe0aa144
|
1
|
|
Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity, file e291c0d7-8fe7-cddb-e053-3a05fe0aa144
|
1
|
|
High-order virtual element method for the homogenization of long fiber nonlinear composites, file e291c0d8-6913-cddb-e053-3a05fe0aa144
|
1
|
|
Brain MR diffusion tensor imaging in Kennedy's disease, file e291c0d8-f7df-cddb-e053-3a05fe0aa144
|
1
|
|
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis, file e291c0d9-021e-cddb-e053-3a05fe0aa144
|
1
|
|
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study), file ee4db205-2ef3-41ad-a5b5-9d227d8c95c6
|
1
|
| Totale |
2.775 |